2022 年杭氧集团股份有限公司 公开发行可转换公司债券 定期跟踪评级报告 !"#$%& !"'()& 本评级机构与评级人员履行了调查和诚信义务，所出具的评级报告遵循了真实、客观、公正的原则。 本报告的评级结论是本评级机构依据合理的内部信用评级标准和程序做出的独立判断，未因评级对象和其他任 何组织或个人的不当影响改变评级意见。 本次跟踪评级依据评级对象及其相关方提供或已经正式对外公布的信息，相关信息的真实性、准确性和完整性由 资料提供方或发布方负责。本评级机构合理采信其他专业机构出具的专业意见，但不对专业机构出具的专业意见 承担任何责任。 本报告并非是某种决策的结论、建议。本评级机构不对发行人使用或引用本报告产生的任何后果承担责任，也不 对任何投资者的投资行为和投资损失承担责任。本报告的评级结论及相关分析并非对评级对象的鉴证意见。鉴于 信用评级工作特性及受客观条件影响，本报告在资料信息获取、评级方法与模型、未来事项预测评估等方面存在 局限性。 *+,-& ./01& (021) 63501349 ./23&上海市黄浦区汉口路 398 号华盛大厦 14 层 4567&www.shxsj.com 上海新世纪资信评 ...

证券代码：002430 证券简称：杭氧股份 公告编号：2025-050 转债代码：127064 转债简称：杭氧转债 杭氧集团股份有限公司 关于"杭氧转债"预计触发转股价格向下修正条件的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 5、本次触发转股价格修正条件的期间从 2025 年 5 月 9 日开始计算，截至 2025 年 5 月 22 日，杭氧集团股份有限公司（以下简称"公司"）股票已有十个 交易日的收盘价格低于当期转股价格的 85%，若后续公司股票收盘价格继续低 于当期转股价格的 85%，预计可能触发《杭氧集团股份有限公司公开发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）中转股价格向下修正条 件。敬请广大投资者注意投资风险。 经深交所"深证上[2022]616号"文同意，公司11.37亿元可转换公司债券于 2022年7月5日起在深交所挂牌交易，转债简称"杭氧转债"，转债代码"127064"。 （三）转股价格调整情况 根据《深圳证券交易所股票上市规则》等有关规定和《募集说明书》的约定， 本次发行的可转债自 2022 ...

Core Viewpoint - Hangyang Co., Ltd. is accelerating its internationalization process by establishing a new subsidiary for a large modular cryogenic equipment manufacturing base in Ningbo, with a total investment of approximately 557 million yuan [1][2][3]. Investment and Project Details - The new subsidiary, Ningbo Hangyang Heavy Equipment Co., Ltd., will be jointly established with China Chemical Engineering Sixth Construction Co., Ltd., with Hangyang holding 65% and China Chemical holding 35% [1][2]. - The total investment for the project is estimated at 557 million yuan, including 420 million yuan for fixed assets and 137 million yuan for working capital, with a construction period of 24 months [2]. Business Performance and Market Position - Hangyang is a leading supplier of air separation equipment in China, maintaining a strong market share in low-temperature petrochemical products such as ethylene cold boxes [1][5]. - In 2024, the company faced short-term profit pressure, with a net profit decline of 24.15%, but showed signs of recovery in 2025 with a 7.85% increase in revenue and a 10.82% increase in net profit in Q1 [1][5]. Research and Development - From 2020 to 2024, Hangyang's cumulative R&D expenses reached 2.009 billion yuan, reflecting its commitment to innovation and technology advancement [1][5]. - The company has been granted a total of 605 patents, including 170 invention patents, indicating a strong focus on technological development [5].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Ke Yi City land project, with the controlling shareholder planning to develop the project instead [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Materials intends to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials [6] - Weifu High-Tech's subsidiary plans to establish a joint venture with Baolong Technology to expand the active suspension motor hydraulic pump business [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chen'an Technology's shareholder is transferring 6.27% of the company's shares to Hefei Guotou, aiming to introduce strategic investors [9] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, with stock trading suspended for up to 10 trading days [11] - Baolong Technology's subsidiary will collaborate with Weifu High-Tech's subsidiary to develop core components for the active suspension system [12] Group 4 - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Supplies, enhancing its product and service range [13] - Weiling Co., Ltd.'s subsidiary has successfully acquired 74.3% of Jiayu Mining for 220 million yuan, focusing on expanding into the non-ferrous metal resource sector [14][15] - Hengshi Technology's subsidiary has been approved for public transfer of shares on the New Third Board [16] Group 5 - Xiang Teng New Materials plans to acquire an additional 12.5% stake in its subsidiary Shanghai Shangda for 25.3 million yuan [17] - ST Texin has extended its employee stock ownership plan by 12 months, reflecting confidence in the company's long-term development [18] - Baili Electric has issued a risk warning regarding its stock price increase, indicating no significant changes in fundamentals [19] Group 6 - Hu Silicon Industry plans to acquire minority stakes in three semiconductor companies for approximately 7.04 billion yuan [20][21] - Demais plans to change its controlling shareholder, leading to a temporary suspension of stock trading [22] - FAW Fuwei has received a notice from a well-known new energy brand for a project expected to generate 1.06 billion yuan in total sales over its lifecycle [23] Group 7 - Hangyang Co. plans to establish a subsidiary for a large modular cryogenic equipment manufacturing project with an estimated investment of 557 million yuan [24] - Jiewate intends to acquire 40.89% of Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [25] - Dingxin Communications has elected a new chairman following the resignation of the previous chairman [26][27] Group 8 - Aofei Entertainment plans to invest 10 million yuan in a partnership to indirectly invest in AI robotics company Xuan Yuan Technology [28] - Huaxi Energy's controlling shareholder has been detained, but the company states that operations remain normal [29] - Yihe Jiaye will change its stock name to "Ruimaite" starting May 21 [30] Group 9 - Zhongjin Environment will change its name to "Southern Pump Industry" effective May 21 [31] - Hong Sifang's subsidiary plans to invest approximately 1.49 billion yuan in a new chemical materials and fertilizers industrial park [32] - Buchang Pharmaceutical's subsidiary has signed a research agreement for MF59 adjuvant with a pharmaceutical company [33] Group 10 - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project [34] - Zhuojin Co. has won a bid for a soil remediation project worth 67.68 million yuan [35] - Xinjiang Jiaojian has been awarded a contract for a highway project valued at 451 million yuan [36] Group 11 - China National Materials Energy's subsidiary has signed a contract for an EPC project in Uzbekistan worth approximately 1.252 billion yuan [37] - Ruixin Microelectronics' shareholder plans to reduce its stake by up to 2% [38] - Shanghai Yizhong's shareholder also plans to reduce its stake by up to 2% [39] Group 12 - Sanyou Medical's controlling shareholder plans to reduce its stake by up to 1.44% [40] - Hangdian Co.'s controlling shareholder plans to reduce its stake by up to 1.93% [41] - Shangwei New Materials' shareholder plans to reduce its stake by up to 3% [42] Group 13 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan [43] - Jiuhua Tourism plans to raise up to 500 million yuan through a private placement for various projects [44] - Yuegui Co. plans to raise up to 900 million yuan for several projects [46]

Core Viewpoint - The company is establishing a joint venture with China Chemical Engineering Sixth Construction Co., Ltd. to create a large modular cryogenic equipment manufacturing base in Ningbo, with a total investment of 557 million yuan [1][3] Group 1: Investment and Project Details - The new subsidiary will have a registered capital of 170 million yuan, with the company holding 65% and China Chemical holding 35% [1] - The project includes a fixed asset investment of 420 million yuan and working capital of 137 million yuan, with a construction period of 24 months [1] Group 2: Business Performance and Strategy - In 2024, the company achieved a revenue of 13.716 billion yuan, a year-on-year increase of 3.06%, with equipment sales contributing 5.065 billion yuan (up 7.22%) and gas business revenue at 8.1 billion yuan (down 1.15%) [2] - The company is transitioning from a pure equipment manufacturer to a comprehensive service provider in the industrial gas sector, leveraging its manufacturing strengths to expand into gas services [2] Group 3: Internationalization and Market Position - The investment will support the company's global business framework, enhancing its international market presence and integrating into major international project supply chains [3] - The company is recognized as a pioneer in China's air separation equipment manufacturing industry, driving technological innovation and expanding its product applications beyond air separation [2]

| 股票代码：002430 | 股票简称：杭氧股份 | 公告编号：2025-048 | | --- | --- | --- | | 转债代码：127064 | 转债简称：杭氧转债 | | 杭氧集团股份有限公司 关于因权益分派实施调整公司回购注销 限制性股票回购价格的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 杭氧集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 5 月 20 日召开了第八届董事会第二十三次会议和第八届监事会第二十次会议，审议通过 了《关于因权益分派实施调整公司回购注销限制性股票回购价格的议案》。公司 于 2025 年 3 月 26 日召开第八届董事会第二十次会议和第八届监事会第十八次 会议，审议通过了《《关于回购注销部分已授予但尚未解锁的限制性股票的议案》； 于 2025 年 4 月 18 日召开 2024 年度股东大会审议通过了《关于回购注销部分已 授予但尚未解锁的限制性股票的提案》。2025 年 5 月 8 日，公司披露《《2024 年年 度权益分派实施公告》《（公告编号：2025-042），2025 年 5 月 ...

浙江天册律师事务所 关于 杭氧集团股份有限公司 2021 年限制性股票激励计划回购价格调整的 法律意见书 浙江省杭州市西湖区杭大路1号黄龙世纪广场A-11 电话：＋86 571 87901111 传真：＋86 571 87901500 http://www.tclawfirm.com 法律意见书 浙江天册律师事务所 关于杭氧集团股份有限公司 2021年限制性股票激励计划回购价格调整 法律意见书 意见书的事实和文件均已向本所披露，并无任何隐瞒、疏漏之处。 3. 本法律意见书仅对公司本次回购价格调整的相关法律事项发表意见。 的法律意见书 编号：TCYJS2025H0686 致：杭氧集团股份有限公司 浙江天册律师事务所（以下简称"本所"）接受杭氧集团股份有限公司（以下简 称"公司"或"杭氧股份"）的委托，担任公司2021年限制性股票激励计划（以下简 称"本次激励计划"）的专项法律顾问，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律、法规和规范 性文件及现行有效的《杭氧集团股份有限公司章 ...

| 股票代码：002430 | 股票简称：杭氧股份 | 公告编号：2025-049 | | --- | --- | --- | | 转债代码：127064 | 转债简称：杭氧转债 | | 杭氧集团股份有限公司 关于投资建设宁波象山大型模块化深冷装备智能制造基地 一期项目暨设立控股子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资概述 杭氧集团股份有限公司（以下简称"公司"或"本公司"）第八届董事会第二 十三次会议、第八届监事会第二十次会议分别审议通过了《关于投资建设宁波象山 大型模块化深冷装备智能制造基地一期项目暨设立控股子公司的议案》。基于空分 装备大型化、模块化、集成化的发展趋势，结合公司国际化战略需求，公司与中国 化学工程第六建设有限公司（以下简称"中化六建"）签订《股东协议》，拟共同 设立宁波杭氧重型装备有限公司（暂定名，最终以当地市场监督管理局核准的名称 为准），在宁波象山投资建设大型模块化深冷装备智能制造基地一期项目，项目总 投资额预计为 55,665 万元，其中，固定资产投资 41,950 万元，流动资金 13,715 万 ...

本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 杭氧集团股份有限公司（以下简称"公司"或"本公司"）于2025年5月20日以通讯 方式召开了第八届监事会第二十次会议，本次会议的通知及会议资料于2025年5月14 日以传真、电子邮件等方式送达各位监事。会议由公司监事会主席董吉琴女士主持， 应参加会议的监事3名，实际参加会议的监事3名。本次会议的召集和召开符合《公 司法》及《公司章程》的有关规定，合法有效。 会议审议了列入议程的议案。按照《公司章程》的规定，与会监事以书面表决 方式对以下议案进行了表决，通过了以下决议： 证券代码：002430 证券简称：杭氧股份 公告编号：2025-047 债券代码：127064 债券简称：杭氧转债 杭氧集团股份有限公司 第八届监事会第二十次会议决议公告 根据《2021年限制性股票激励计划》（草案修订稿）（以下简称"《激励计 划》"）的约定，同意基于2024年年度权益分派实施情况对限制性股票回购价格进 行调整，本次调整后，首次授予的限制性股票回购价格由10.75元/股调整为10.45元/ 股；第一批预留部分限制性股票回购价格由12 ...